MSCs are isolated from the bone marrow of healthy adult human donors and are used to treat SR-aGVHD in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
本次“再生障碍性贫血”专场特邀中国医学科学院血液病医院的张凤奎教授担任大会主席,施普林格·自然集团的大中华区总裁Arnout Jacobs先生作为特邀嘉宾致开场词,北京协和医院的韩冰教授担任主要讲者,来自法国的Régis Peffault de Latour教授、日本的Shinji Nakao教授和韩国的Jun Ho Jang教授作为讨论嘉宾参与了热点问题的探讨。
3 Allogeneic HSCT has been reported to be feasible and effective in the short term and medium term (ie, 6 months to 3 years), with donors being HLA-identical siblings (most cases), a haplo-identical ...